Sclerosing mesenteritis is part of a spectrum (including mesenteric lipodystrophy and mesenteric panniculitis) of idiopathic primary inflammatory and fibrotic processes that affect the mesentery. Pathophysiologically, these processes may affect the integrity of the gastrointestinal lumen and mesenteric vessels by a mass effect.There is considerable overlap between these inflammatory conditions often leading to diagnostic and therapeutic confusion.
Glucocorticoid drugs such as prednisone, which relieve inflammation. They may be used in combination with azathioprine and colchicine.Hormonal therapy such as tamoxifen has also been shown to work. Sometimes hormonal therapy is used together with glucocorticoid drugs.Several other medications such as azathioprine, colchicine, Cyclophosphamide and thalidomide.
History of sclerosing mesenteritis is not well understood, because of the rarity of this condition. In a five-year follow-up report of 47 patients with mesenteric Sclerosing mesenteritis, 65 percent were alive, and in those who died, one-half of the deaths were due to malignancy.Sclerosing mesenteritis is chronic inflammation and fibrosis of the mesentery of unknown etiology. Fewer than 200 cases have been reported in the literature.